- Home
- SFHG vs INAB Comparison
SFHG vs INAB Comparison
Compare SFHG & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFHG
- INAB
- Stock Information
- Founded
- SFHG 1993
- INAB 2016
- Country
- SFHG Hong Kong
- INAB United States
- Employees
- SFHG N/A
- INAB N/A
- Industry
- SFHG Publishing
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SFHG Consumer Discretionary
- INAB Health Care
- Exchange
- SFHG Nasdaq
- INAB Nasdaq
- Market Cap
- SFHG 11.7M
- INAB 10.6M
- IPO Year
- SFHG 2024
- INAB 2021
- Fundamental
- Price
- SFHG $0.50
- INAB $1.88
- Analyst Decision
- SFHG
- INAB Strong Buy
- Analyst Count
- SFHG 0
- INAB 2
- Target Price
- SFHG N/A
- INAB $108.00
- AVG Volume (30 Days)
- SFHG 54.2K
- INAB 63.7K
- Earning Date
- SFHG 10-30-2025
- INAB 11-10-2025
- Dividend Yield
- SFHG N/A
- INAB N/A
- EPS Growth
- SFHG N/A
- INAB N/A
- EPS
- SFHG N/A
- INAB N/A
- Revenue
- SFHG $19,577,200.00
- INAB N/A
- Revenue This Year
- SFHG N/A
- INAB N/A
- Revenue Next Year
- SFHG N/A
- INAB N/A
- P/E Ratio
- SFHG N/A
- INAB N/A
- Revenue Growth
- SFHG 3.56
- INAB N/A
- 52 Week Low
- SFHG $0.55
- INAB $1.91
- 52 Week High
- SFHG $24.00
- INAB $12.53
- Technical
- Relative Strength Index (RSI)
- SFHG 21.04
- INAB 32.98
- Support Level
- SFHG $0.58
- INAB $2.04
- Resistance Level
- SFHG $0.68
- INAB $2.15
- Average True Range (ATR)
- SFHG 0.03
- INAB 0.10
- MACD
- SFHG -0.00
- INAB -0.02
- Stochastic Oscillator
- SFHG 2.49
- INAB 18.27
About SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.